Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
J Pharm Pharmacol ; 49(10): 981-4, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9364406

ABSTRACT

The effect of the Ca(2+)-channel antagonist nicardipine on the basal tone of six segments (duodenum, jejunum, ileum, proximal colon, distal colon and rectum) of the guinea-pig intestine has been investigated in muscle preparations. Nicardipine reduced the basal tone of the proximal and distal colon but not of the duodenum, jejunum, ileum and rectum. Similarly, when each segment was incubated in Ca(2+)-free medium, the basal tone of the proximal and distal colon, but not that of the other four segments, was reduced. The reduced basal tone recovered after cumulative addition of Ca2+ in both colon preparations. The basal tone of the distal colon was partly reduced by tetrodotoxin, atropine and clonidine. Conversely, L-type Ca(2+)-channel antagonists (Cd2+, verapamil and nicardipine), but not the T-type Ca(2+)-channel antagonist Ni2+, completely reduced the basal tone of the distal colon. These results indicate that in the regulation of basal tone there are additional regional differences in the effect of Ca2+ influx into the cells from the extracellular fluid which might involve L-type-like Ca2+ channels and might partly be because of neuronal factors.


Subject(s)
Calcium Channel Blockers/pharmacology , Calcium/pharmacology , Intestines/drug effects , Adrenergic alpha-Agonists/pharmacology , Animals , Atropine/pharmacology , Guinea Pigs , In Vitro Techniques , Intestines/anatomy & histology , Male , Muscarinic Antagonists/pharmacology , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Narcotic Antagonists/pharmacology , Nicardipine/pharmacology , Organ Specificity , Tetrodotoxin/pharmacology
2.
Arzneimittelforschung ; 46(9): 919-22, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8876942

ABSTRACT

To clarify the anti-gastric acid secretory mechanism of 1,6-dihydro-2-[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidinecarbo xylic acid (CAS 98772-05-5, MAR-99), the relationship between gastric acid secretion and gastric mucosal mast cell (MMC) was studied and the effect of this compound on these parameters was examined and compared with anti-allergic drugs (mast cell stabilizers) and anti-ulcer drugs. The release of histamine from MMC cultured from bone marrow and connective tissue mast cell (CTMC) isolated from peritoneal cavity was found to be induced by the addition of ethanol (final conc. 17.5%), and the inhibitory effect on histamine release from MMC is closely associated with the anti-gastric secretory effect. That is to say, MAR-99 (10(-9)-10(-7) mol/l) inhibited histamine release from MMC induced by ethanol in a concentration-dependent manner. The action of MAR-99 on MMC was more sensitive than that of CTMC. In addition, MAR-99 (100 mg/kg i.d.) suppressed gastric acid secretion. On the other hand, anti-allergic drugs (mast cell stabilizers), such as DSCG and tranilast (both 10(-7) mol/l), markedly inhibited histamine release from CTMC induced by ethanol, but these drugs (10(-8)-10(-7) mol/l) showed only a tendency to prevent the release of histamine from MMC. Furthermore these drugs (both 100 mg/ kg i.d.) had no effects on gastric acid secretion. Equally anti-ulcer drugs, such as cetraxate, teprenone and sofalcone, had no effects on histamine release from mast cells of two types and gastric acid secretion. From these results, it was suggested that MMC is closely correlated with gastric acid secretion, and the anti-gastric secretory effect of MAR-99 may mainly contribute to prevent the degranulation of MMC.


Subject(s)
Anti-Ulcer Agents/pharmacology , Gastric Acid/metabolism , Gastric Mucosa/cytology , Gastric Mucosa/metabolism , Mast Cells/metabolism , Pyrimidines/pharmacology , Animals , Bone Marrow/drug effects , Bone Marrow/metabolism , Bone Marrow Cells , Central Nervous System Depressants/pharmacology , Connective Tissue/drug effects , Connective Tissue Cells , Depression, Chemical , Ethanol/pharmacology , Histamine Release/drug effects , Male , Mast Cells/drug effects , Mice , Mice, Inbred Strains , Pylorus/physiology , Rats , Rats, Sprague-Dawley
3.
Arzneimittelforschung ; 46(8): 779-83, 1996 Aug.
Article in English | MEDLINE | ID: mdl-9125278

ABSTRACT

To disclose the cytoprotective mechanism of 1,6-dihydro-2[2-(2-methyoxypropoxy)anilino]-6-oxo-5-pyrimidinecarb oxylic acid (CAS 98772-05-5, MAR-99), the effect of this compound on the microvascular injury in gastric mucosa induced by 99.5% ethanol in rats was studied. In this experiment, it was found that the elevation of vascular permeability observed at the early state of ethanol-induced gastric mucosal injury was closely correlated with the combined action of histamine and slow reacting substance (leukotriene C4, LTC4). MAR-99 (0.3-10 mg/kg p.o.) prevented dose-dependently the increase in vascular permeability. Furthermore, MAR-99 (10 mg/kg p.o.) improved the decrease in the number of histamine containing cells and histamine content, and prevented the production of LTC4. These results suggest that MAR-99 exerts its anti-microvascular injury effect by regulating the release of histamine and the production of LTC4 in glandular stomach against ethanol, and this effect may contribute to the anti-lesion effect of this compound.


Subject(s)
Anti-Ulcer Agents/pharmacology , Gastric Mucosa/drug effects , Pyrimidines/pharmacology , Animals , Capillary Permeability/drug effects , Disease Models, Animal , Ethanol , Gastric Mucosa/blood supply , Gastric Mucosa/physiopathology , Guinea Pigs , Histamine Release/drug effects , Leukotriene C4/metabolism , Male , Rats , Rats, Sprague-Dawley , Tranexamic Acid/analogs & derivatives , Tranexamic Acid/pharmacology
4.
Chem Pharm Bull (Tokyo) ; 43(11): 2021-3, 1995 Nov.
Article in English | MEDLINE | ID: mdl-8575039

ABSTRACT

With a view to finding more effective antiulcer agents, a series of 2-benzylthio-5,6,7,8-tetrahydro-4(3H)-quinazolinones and related compounds were synthesized and evaluated in a histamine-stimulated gastric secretion model. The sodium salt of the 2-(dimethylamino)benzylthio derivative (8) showed gastric mucosal protection and gastric antisecretion activities, and was also effective against experimental gastric and duodenal ulcers induced by some ulcerogenic agents. Based on a comparison of the antiulcer properties of 8 with those of the lead compounds (1 and 2) and cimetidine, it appears that, for improvement of antiulcer activity, the reduction of gastric acidity is a more important factor than the reduction of gastric volume output or gastric total acid output.


Subject(s)
Anti-Ulcer Agents/pharmacology , Gastric Mucosa/drug effects , Quinazolines/pharmacology , Animals , Anti-Ulcer Agents/chemistry , Anti-Ulcer Agents/therapeutic use , Aspirin/administration & dosage , Aspirin/toxicity , Cimetidine/administration & dosage , Cimetidine/pharmacology , Cimetidine/therapeutic use , Disease Models, Animal , Duodenal Ulcer/drug therapy , Epirizole/administration & dosage , Epirizole/toxicity , Ethanol/administration & dosage , Ethanol/toxicity , Gastric Acid/metabolism , Gastric Mucosa/injuries , Histamine/administration & dosage , Histamine/toxicity , Indomethacin/administration & dosage , Indomethacin/toxicity , Male , Quinazolines/chemistry , Quinazolines/therapeutic use , Rats , Rats, Sprague-Dawley , Stomach Ulcer/drug therapy , Structure-Activity Relationship
5.
Chem Pharm Bull (Tokyo) ; 43(6): 1042-4, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7543824

ABSTRACT

With the aim of applying mast cell-stabilizing agents as antiulcer agents, N-(1H-tetrazol-5-yl)-2-anilino-5-pyrimidinecarboxamides were synthesized, and initially evaluated pharmacologically for activity in the rat passive cutaneous anaphylaxis test by oral administration. The most active compound 6 was proved to inhibit potently the release of histamine from passively sensitized rat peritoneal mast cells in vitro. When compared with other mast cell-stabilizing agents and an antiulcer agent, compound 6 was found to show excellent gastric mucosal protection and gastric antisecretion activities. Furthermore, compound 6 revealed good activity against acidified aspirin ulcer in rats and water-immersion stress ulcer in rats.


Subject(s)
Anti-Ulcer Agents/chemical synthesis , Histamine Release/drug effects , Mast Cells/metabolism , Pyrimidines/chemical synthesis , Tetrazoles/chemical synthesis , Animals , Anti-Ulcer Agents/pharmacology , Aspirin , Cimetidine/pharmacology , Cromolyn Sodium/pharmacology , Ethanol , Histamine H1 Antagonists/pharmacology , Mast Cells/drug effects , Passive Cutaneous Anaphylaxis/drug effects , Peritoneal Cavity/cytology , Pyrimidines/pharmacology , Rats , Stomach Ulcer/chemically induced , Stomach Ulcer/drug therapy , Tetrazoles/pharmacology , ortho-Aminobenzoates/pharmacology
6.
Arzneimittelforschung ; 44(5): 620-6, 1994 May.
Article in English | MEDLINE | ID: mdl-8024635

ABSTRACT

1,6-dihydro-2-[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidinecarbo xylic acid, (MAR-99, CAS 98772-05-5) (10-30 mg/kg i.g.) improved the reduction of gastric blood flow rate induced by the administration of 99.5% ethanol or acidified-acetylsalicylic acid (ASA). In addition, MAR-99 (3 x 10(-6)-3 x 10(-5) mol/l) protected dose-dependently the damage of epithelial cells induced by ulcerogenic agents such as ethanol or acidified-ASA. MAR-99 (1-10 mg/kg p.o.) prevented dose-dependently the reduction of hexosamine content in glandular stomach. Furthermore, MAR-99 (10-30 mg/kg i.g.) improved the decrease in gastric potential difference induced by 99.5% ethanol and acidified-ASA. MAR-99 (10-30 mg/kg p.o.) significantly inhibited the lesion formation induced by 99.5% ethanol and such effect of this compound was not attenuated by the pretreatment with indomethacin. Furthermore MAR-99 (10 and 30 mg/kg p.o.) had no effect on the prostaglandins (PGE2 and I2) contents in the stomach of normal rats. In pylorus-ligated rats, MAR-99 (3-100 mg/kg i.d.) showed a weak or no effect on acidity and pepsin activity in gastric juice, although this compound decreased dose-dependently the volume of gastric juice. In perfused stomachs, MAR-99 (30-100 mg/kg i.d.) slightly prevented the acid secretion induced by carbachol and pentagastrin. However, MAR-99 did not affect the acid secretion stimulated by histamine. These results indicated that anti-ulcer effect of MAR-99 was mainly due to maintenance of the gastric mucosal resistance.


Subject(s)
Anti-Ulcer Agents/pharmacology , Gastric Mucosa/physiology , Pyrimidines/pharmacology , Animals , Aspirin/pharmacology , Carbachol/pharmacology , Epithelial Cells , Epithelium/drug effects , Ethanol/pharmacology , Gastric Acid/metabolism , Gastric Mucosa/drug effects , Gastric Mucosa/metabolism , Hexosamines/metabolism , Histamine/pharmacology , In Vitro Techniques , Indomethacin/pharmacology , Male , Membrane Potentials/drug effects , Mucus/metabolism , Pentagastrin/pharmacology , Rats , Rats, Sprague-Dawley , Regional Blood Flow/drug effects , Stomach/blood supply
7.
Arzneimittelforschung ; 44(4): 509-13, 1994 Apr.
Article in English | MEDLINE | ID: mdl-8011005

ABSTRACT

The effects of 1,6-dihydro-2-[2-(2-methylpropoxy) anilino]-6-oxo-5-pyrimidinecarboxylic acid (MAR-99, CAS 98772-05-5) on various experimental gastric ulcers were studied in rats. MAR-99 (3-100 mg/kg, p.o. or i.d.) showed the anti-ulcer effect in Shay-, stress, acetylsalicylic acid (ASA)- and compound 48/80-ulcer models and significantly accelerated healing of acetic acid-induced gastric ulcer in rats. In addition, MAR-99 (1-10 mg/kg p.o.) decreased dose-dependently the gastric mucosal damage induced by necrotizing agents such as 99.5% ethanol, 0.6N HCl and 0.2 N NaOH. These results indicate that MAR-99 may be useful for the treatment of gastric ulcer in human.


Subject(s)
Anti-Ulcer Agents/chemical synthesis , Pyrimidines/chemical synthesis , Stomach Ulcer/prevention & control , Acetates , Animals , Anti-Ulcer Agents/pharmacology , Aspirin , Cimetidine/pharmacology , Ethanol , Hydrochloric Acid , Male , Pylorus/physiology , Pyrimidines/pharmacology , Rats , Rats, Sprague-Dawley , Sodium Hydroxide , Stomach Ulcer/chemically induced , Stomach Ulcer/etiology , Stress, Psychological/complications , Tranexamic Acid/analogs & derivatives , Tranexamic Acid/pharmacology , p-Methoxy-N-methylphenethylamine
8.
Br J Pharmacol ; 109(4): 1226-31, 1993 Aug.
Article in English | MEDLINE | ID: mdl-8401933

ABSTRACT

1. Cibenzoline, a class I antiarrhythmic agent, was investigated for its effect on the ATP-sensitive K+ channel of pancreatic beta-cells by the patch clamp technique. 2. In perforated patch clamp experiments, cibenzoline depolarized the membrane of single beta-cells and thereafter, caused firing of action potentials in the presence of 2.8 mM glucose. 3. Cibenzoline inhibited the activity of the ATP-sensitive K+ channel in cell-attached recordings in the presence of 2.8 mM glucose and evoked repetitive fluctuations of the baseline current, apparently reflecting the action potentials of the beta-cell. 4. In whole-cell clamp experiments, time-independent outward current was induced by depleting cytoplasmic ATP with 0.1 mM ATP and 0.1 mM ADP in the solution contained in the pipette. The outward current was inhibited by cibenzoline in a dose-dependent manner in the concentration range of 1 microM to 100 microM and half maximum inhibition occurred at 1.5 microM. 5. Cibenzoline blocked substantially the ATP-sensitive K+ channel current when applied at the inner side of the membrane in isolated inside-out membrane patches. 6. It is concluded that cibenzoline blocks the ATP-sensitive K+ channel of pancreatic beta-cells and, thereby, stimulates insulin secretion at sub-stimulatory levels of glucose.


Subject(s)
Adenosine Triphosphate/antagonists & inhibitors , Anti-Arrhythmia Agents/pharmacology , Imidazoles/pharmacology , Islets of Langerhans/metabolism , Potassium Channels/drug effects , Action Potentials/drug effects , Adenosine Triphosphate/pharmacology , Animals , Glucose/pharmacology , In Vitro Techniques , Islets of Langerhans/drug effects , Kinetics , Rats , Rats, Wistar , Tolbutamide/pharmacology
10.
Peptides ; 8(2): 257-60, 1987.
Article in English | MEDLINE | ID: mdl-2954032

ABSTRACT

The release of immunoreactive (ir-) rat atrial natriuretic peptide (rANP) with volume expansion in in situ retrograde perfused rat heart was examined. The volume expansion induced by the infusion of the perfusion medium into the right atrium increased the mean right atrial pressure and the ir-rANP release without changing the rate of the heart beat. There was a significant correlation between the peak values of ir-rANP release and those of mean atrial pressure. The bilateral cervical vagotomy did not effect the ir-rANP release induced by the volume expansion. Therefore, it is highly likely that the stimulatory effect of volume expansion on rANP release is due to, at least in part, the atrial distension accompanied by an increase in mean atrial pressure, not involving a vagal system.


Subject(s)
Atrial Natriuretic Factor/metabolism , Heart/physiology , Animals , Heart/anatomy & histology , In Vitro Techniques , Male , Perfusion , Radioimmunoassay , Rats , Rats, Inbred Strains , Vagotomy
11.
Microbiol Immunol ; 31(3): 261-74, 1987.
Article in English | MEDLINE | ID: mdl-3497327

ABSTRACT

The culture supernatants of unstimulated T cells (TCS) from asthmatic patients with elevated serum IgE were tested for IgE-binding factors (IgE-BFs) displaying the IgE-potentiating activity. The IgE-BFs were detected by their ability to inhibit the rosetting of RPMI 8866 cells with ox erythrocytes coupled with mouse monoclonal antibody (E-Mab) specific to Fc receptors for IgE (Fc epsilon R). TCS showing the rosette-inhibiting activity significantly enhanced the spontaneous IgE synthesis by B cells of allergic individuals. Interestingly, rosette-inhibiting factors could be removed by absorption with IgE-Sepharose from which they were subsequently eluated with acid buffer, indicating that the rosette inhibition was indeed mediated by IgE-BFs. In addition, such IgE-BFs had affinity for concanavalin A and lost their IgE-potentiating activity after treatment with trypsin and neuraminidase. In contrast, T cells treated with tunicamycin released IgE-suppressing factors capable of inhibiting the IgE-potentiating activity of TCS derived from untreated T cells. On the other hand, the culture supernatants from subpopulations depleted of Fc epsilon R+ T cells but not of Fc gamma R+ T cells contained neither rosette-inhibiting factors nor IgE-potentiating factors, suggesting that IgE-BFs were released by in vivo pre-activated Fc epsilon R+ T cells. With regard to circulating Fc epsilon R+ T cells determined by E-Mab, they were significantly higher in asthmatic patients with elevated serum IgE (0.77 +/- 0.15%) than in normal subjects (0.17 +/- 0.07%) in spite of a very small proportion of T cells bearing Fc epsilon R.


Subject(s)
Asthma/immunology , Immunoglobulin E/biosynthesis , Lymphokines/immunology , Prostatic Secretory Proteins , T-Lymphocytes/immunology , Cell Line , Humans , Lymphokines/analysis , Receptors, Fc/immunology , Rosette Formation
15.
Clin Exp Pharmacol Physiol ; 6(2): 123-8, 1979.
Article in English | MEDLINE | ID: mdl-421367

ABSTRACT

1. The effects of intraperitoneal injection of 6-hydroxydopamine (6-OHDA) on the levels and the turnover of brain catecholamines and the levels of plasma corticosterone were studied in rats. 2. Two weeks after intraperitoneal injection of 6-OHDA (150 mg/kg) a virtually complete disappearance of cardiac noradrenaline was observed. 3. An increment and an accelerated turnover of noradrenaline in the hypothalamus was observed 2 weeks after peripheral administration of 6-OHDA (150 mg/kg). 4. There was no change in the levels and the turnover of noradrenaline in the cortex of the rats so treated. 5. There was not change in the levels and the turnover of dopamine in either the hypothalamus or the cortex of the 6-OHDA-treated rats. 6. An increment and an accelerated turnover of hypothalamic noradrenaline were not associated with any change in plasma corticosterone.


Subject(s)
Brain/metabolism , Dopamine/metabolism , Hydroxydopamines/pharmacology , Norepinephrine/metabolism , Animals , Brain/drug effects , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Corticosterone/blood , Heart/drug effects , Hydroxydopamines/administration & dosage , Hypothalamus/drug effects , Hypothalamus/metabolism , Injections, Intraperitoneal , Male , Myocardium/metabolism , Rats
16.
Acta Endocrinol (Copenh) ; 89(3): 432-7, 1978 Nov.
Article in English | MEDLINE | ID: mdl-707004

ABSTRACT

The possibility that intraventricular administration of 5,6-dihydroxytryptamine (5,6-DHT) can cause a development of denervation hypersensitivity to central 5-hydroxytryptamine (5-HT) was examined in rats with special reference to the pituitary-adrenocortical functions. Pretreatment with intraventricular injection of 5,6-DHT itself did not affect the basal concentrations or stress-induced increases of plasma B. The same pre-treatment, however, elicited augmented responses to subcutaneous injection of 5-HTP, i.e. there was a significant rise in the concentrations of plasma B as compared with those in the controls. These results suggest a development of denervation hypersensitivity to 5-HT following intraventricular injection of 5,6-DHT.


Subject(s)
5,6-Dihydroxytryptamine/pharmacology , Brain/metabolism , Hypothalamo-Hypophyseal System/drug effects , Pituitary-Adrenal System/drug effects , Serotonin/pharmacology , 5,6-Dihydroxytryptamine/administration & dosage , Animals , Corticosterone/blood , Darkness , Denervation , Injections, Intraventricular , Light , Male , Rats , Serotonin/metabolism , Serotonin/physiology , Stress, Physiological
SELECTION OF CITATIONS
SEARCH DETAIL
...